Epilepsy

Neurology News Network for the week ending January 4, 2020.

The director of the Pediatric Epilepsy Program at Weill Cornell Medicine detailed the reasons behind why patients with infantile spasms do not receive recommended care.

The approvals introduced several new classes of drugs, including the ditans and gepants in migraine, as well as novel formulations that can ease the administration of treatments for Parkinson disease and epilepsy.

The staff epileptologist at Cleveland Clinic’s Epilepsy Center spoke to the benefits of telemedicine for patients with epilepsy, and how the practice can alleviate a number of burdens.

Catch up on some of our most popular Peer Exchange panels with experts in the field, including discussions on epilepsy, migraine, multiple sclerosis, and more.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Daniel Lowenstein, MD.

The professor of neurology at NYU Langone offered insight into the state of affairs with current seizure rescue medications and added her insight into how intranasal diazepam may improve the patient experience.

Catch up on some of our most popular video interviews with leaders in the field, including discussions with Imad Najm, MD, James Leverenz, MD, Richard Isaacson, MD, and more.

The director of Infantile Spasms Program at UCLA Mattel Children’s Hospital discussed why learning more about patients with infantile spasms may lead to further breakthroughs on the origins of autism spectrum disorder.

The professor of neurology at NYU Langone spoke to her clinical experience with cenobamate and how she anticipates it might be utilized once it becomes commercially available.

The staff epileptologist at Cleveland Clinic’s Epilepsy Center spoke to her experience using telemedicine to manage patients with epilepsy and some of the unexpected perspectives it offers.

The second of 2 identical trials investigating 2 doses of low-dose fenfluramine (Fintepla) is set to be completed in early 2020, as the agent awaits FDA approval.

Panelists review the delicate process of introducing a new medication to a treatment regimen and the creative endeavors employed to improve adherence.

The director of Infantile Spasms Program at UCLA Mattel Children’s Hospital detailed his personal experience counseling parents whose first child has infantile spasms.

The professor of neurology at NYU Langone discussed cenobamate’s potential as a treatment option for patients who have uncontrolled seizures, as well as its ability to bring a high number of patients toward complete seizure freedom.

Two lots of the oral seizure treatment have been recalled and should be returned to the manufacturer.

The drug safety warning stems from a review of case reports and clinical studies that showed use of gabapentinoids with or without opioids is associated with serious breathing difficulties.

The professor and chief of pediatric neurology, and director of the comprehensive epilepsy program and neuroscience institute at Le Bonheur Children’s Hospital, detailed his experience with patients treated with perampanel.

The director of epilepsy surgery and associate professor of neurosurgery at UC Irvine spoke to the advances that have been made in epilepsy surgery and in noninvasive or minimally invasive techniques, as well as the impact they’ve had on outcomes.

The CEO and Chairman of the Board of Directors at INSIGHTEC offered his perspective on how technologies such as focused ultrasound can help shape the future of neurologic care.

The medical director of the Comprehensive Epilepsy Clinic at Nicklaus Children’s Hospital discusses his early stage gene therapy trial for Dravet syndrome.

The CEO of INSIGHTEC offered insight into what challenges in the neurologic space the company plans to tackle in the coming years, and why 2020 marks the start of the “Century of the Brain.”

The assistant professor of psychology at East Carolina discussed how to improve adherence in young adults and children with epilepsy, and how physicians can go about checking quality of life in patients.

A new trial will aim to confirm the findings of a previous study that showed novel combinations of peripherally circulating proteins coupled with risk factors can provide a diagnostic tool with significant clinical unity.

Neurology News Network for the week ending December 14, 2019.

The assistant professor of psychology at East Carolina University spoke to the challenges of overcoming adherence issues in patients with epilepsy, for whom it is so vital.

Electroencephalography-functional magnetic resonance imaging can better identify the epileptogenic focus, resulting in a direct impact on patient management and surgery decision-making.

The professor of neurology and pediatrics and director of the Pediatric Epilepsy Center at the University of California, San Francisco, discussed his personal experience with fenfluramine and the advantages that the drug may present when treating patients with Dravet syndrome.

Full results from the single-dose crossover study requested by the FDA were reported at AES 2019, along with multi-dose safety and efficacy data.

Patients were more affected by seizure cluster control and need for additional midazolam dosing than post-dose somnolence.